ISSN 1866-8836
Клеточная терапия и трансплантация

NM-05. Histological characteristic of nasal mucosa after the usage of mesenchymal stem cells in the treatment of chronic polyposis rhinosinusitis: preliminary results of observation

Anastasia A. Nidelko1, Elvira A. Shulepova2, Svetlana N. Ryabtseva3, Veronika E. Mantivoda4, Natalia G. Antonovich4, Andrey E. Goncharov4, Valery L. Chekan2, Yulia E. Eremenko1

1 Republican Scientific and Practical Center of Otorhinolaryngology, Minsk, Republic of Belarus
2 Belarusian Medical Academy of Postgraduate Education, Minsk, Republic of Belarus
3 Institute of Physiology, National Academy of Sciences, Minsk, Republic of Belarus
4 Institute of Biophysics and Cell Engineering, National Academy of Sciences, Minsk, Republic of Belarus

Contact: Dr. Anastasiya A. Nidelko, phone: +(375) 17 2001893, e-mail:

doi 10.18620/ctt-1866-8836-2023-12-3-1-176


Usage of mesenchymal stem cells (MSCs) leads to an increased production of pro-inflammatory cytokines, suppresses immune inflammation and stimulates the definition of tissues at the site of their attachment.

Materials and methods

The samples of nasal mucosa used in this study were taken from the patients with chronic polypous rhinosinusitis (CPRS) aged 24 to 67 years, who were treated at the Republican Research and Practical Center for Otorhinolaryngology since November 2021 to August 2023. The main group (n=8) included patients who underwent cell therapy either on the day of surgery, or within a period of 2 to 5 months after the surgery. The average age of patients was 42.2±3.3 years (M±m), including 3 women and 5 males (37.5% and 62.5%, respectively). The control group (n=6) included patients who did not receive cell therapy. The mean age of the patients was 43.6±3.5 years (M±m), including 2 women and 4 males (33% and 67%, respectively). The introduction of a biomedical cell product based on MSCs onto the olfactory lining at a dose of 15-20×10^6 cells was performed under local application anesthesia with a 10% lidocaine solution, or intravenous anesthesia into mucous membrane of the nasal cavity which was practically unaffected by the pathological process (the areas of middle turbinates, lateral wall of the nasal cavity, upper portions of the nasal septum, upper section of inferior turbinates). Histological evaluation of the nasal mucosa was performed up to 3 months and ca. 1 year after cell therapy in the main group and, after surgery, in the control group.

Results and discussion

Inflammatory infiltration was noted in the mucous membrane of nasal cavity in both groups up to 3 months after MSCs introduction. In the control group, inflammatory infiltration was moderate or severe, being represented by lymphocytes and macrophages, with formation of single lymphatic follicles (in single observations). In the control group, there were also signs of inflammatory process which manifested by accumulation of eosinophils or neutrophils in the epithelial layer or stroma of the nasal mucosa. In the main group, the severity of inflammatory infiltration was pronounced at a mild or moderate degree, without formation of lymphatic follicles. There were no signs of active inflammatory process in the main group. After a year of observation, inflammatory infiltration in the mucosa of patients was pronounced at a mild degree in both study groups. However, signs of active inflammatory process with accumulation of eosinophils and stromal edema of nasal mucosa were more often detected in the control group.


Preliminary analysis of histological preparations of nasal mucosa samples after cell therapy in addition to standard treatment of CPMS indicates a decrease in the inflammatory process in the nasal mucosa of patients compared with the control group.


Chronic polypous rhinosinusitis, cell therapy, mesenchymal stem cells, immune therapy, histological examination.

Supplement 12-3

Download PDF version

doi 10.18620/ctt-1866-8836-2023-12-3-1-176

Back to the list